Printer Friendly
The Free Library
21,446,309 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, March 22 (DDMAC).

After reviewing a journal advertisement for the company's stroke drug, Aggrenox (aspirin/extended-release dipyridamole dipyridamole /di·py·rid·a·mole/ (di?pi-rid´ah-mol) a platelet inhibitor and coronary vasodilator used to prevent thromboembolism associated with mechanical heart valves, to treat transient ischemic attacks, and as an adjunct in ), DDMAC DDMAC Division of Drug Marketing, Advertising and Communications  cited Boehringer Ingelheim for unsubstantiated superiority claims.

According to the FDA-approved labeling, Aggrenox is a combination antiplatelet agent indicated "to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis."

But the ad, which was submitted to FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 in September, contained suggestions that Aggrenox may be more effective than Plavix (clopidogrel), a stroke medication jointly manufactured by Bristol-Myers Squibb and Sanofi-Aventis. The agency contended, however, that Boehringer Ingelheim based the claims of superiority on "indirect comparisons" that were not supported by clinical research.

Additionally, DDMAC stated that Boehringer Ingelheim failed to include adequate risk information in the Aggrenox promotion; in particular, the company failed to include a precaution concerning the risk of intracranial hemorrhage.

The main part of the ad also failed to include warnings concerning alcohol consumption, coagulation coagulation (kōăg'ylā`shən), the collecting into a mass of minute particles of a solid dispersed throughout a liquid (a sol), usually followed by the precipitation or  abnormalities, peptic ulcer disease Peptic ulcer disease (PUD)
A stomach disorder marked by corrosion of the stomach lining due to the acid in the digestive juices.

Mentioned in: Indigestion

peptic ulcer disease See Duodenal ulcer, Gastric ulcer, GERD.
 and pregnancy. F-B; Doc. 13419W
COPYRIGHT 2005 Washington Information Source, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:CFSAN and DDMAC PROMO UNTITLED LETTERS
Publication:Warning Letter Bulletin
Date:Apr 1, 2005
Words:165
Previous Article:AstraZeneca Pharmaceuticals LP, Wilmington, DE, March 8 (DDMAC).
Next Article:Direct Marketing Advertising Distributors, Hicksville, NY, Feb. 23 (CFSAN).
Topics:



Related Articles
Boehringer Ingelheim obtains United States patent.
DDMAC promo untitled letter.
DDMAC promo untitled letter.
AstraZeneca Pharmaceuticals LP, Wilmington, DE, March 8 (DDMAC).
Pfizer, New York, April 13 (DDMAC).
Bayer Pharmaceuticals, West Haven, CT, April 13 (DDMAC).
Watson Pharmaceuticals, Morristown, NJ, May 2 (DDMAC).
Eli Lilly and Co., Indianapolis, June 14 (DDMAC).
Actelion Pharmaceuticals US, San Francisco, July 20 (DDMAC).
Eli Lilly and Co., Indianapolis, July 27 (DDMAC).

Terms of use | Copyright © 2013 Farlex, Inc. | Feedback | For webmasters | Submit articles